On May 2, 2023, the U.S. Food and Drug Administration (FDA) took additional steps to support the use of decentralized clinical trials (DCTs) by releasing a new draft guidance titled.
Food and Drug Administration’s guidance investigators can consider telehealth visits so long as no in-person interaction is needed, FDA expects that protocol specify which visits conducted via telehealth and which require the participant to either be seen in person
Over the past few years, the life sciences and healthcare industries have experienced a notable increase in focus and interest in decentralized clinical trials (DCTs), in which some or.